Previous 10 | Next 10 |
MediWound Ltd. (MDWD) Q3 2019 Earnings Conference Call November 14, 2019, 08:30 AM ET Company Participants Jeremy Feffer - IR Sharon Malka - CEO Boaz Gur-Lavie - CFO Conference Call Participants Anthony Petrone - Jefferies & Co. Bryan Bergin - Cowen Presentation ...
MediWound (NASDAQ: MDWD ): Q3 GAAP EPS of -$0.11 beats by $0.04 . More news on: MediWound Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
Total revenues of $5.1 million, driven primarily by revenues from development services Initiated U.S. NexoBrid expanded access treatment (NEXT) protocol, with plans on track for NexoBrid® BLA filing in the second quarter of 2020 Expected to initiate patient treatment in Escha...
YAVNE, Israel, Nov. 06, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the ...
CAMBRIDGE, Mass. and YAVNE, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) and MediWound Ltd. (NASDAQ: MDWD) today announced initiation of the NexoBrid ® expanded access treatment protocol (NEXT) to treat burn patients with deep partial- and full-thicknes...
YAVNE, Israel, Sept. 03, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound care management, today announced a significant presence at the 18 th European Burns As...
MediWound Ltd. (MDWD) Q2 2019 Results Earnings Conference Call August 13, 2019 08:30 AM ET Company Participants Monique Kosse - LifeSci Advisors Sharon Malka - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call Participants Anthony Petrone - ...
MediWound (NASDAQ: MDWD ): Q2 Non-GAAP EPS of -$0.12 misses by $0.09 ; GAAP EPS of $0.47 beats by $0.50 . More news on: MediWound Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
Total revenues of $20.7 million, driven primarily by the upfront payment from Vericel for NexoBrid ® license agreement BARDA committed additional $21 million to fund NexoBrid ® expanded access treatment protocol Confirmed BLA submission plans in a pre-BLA meeting with...
YAVNE, Israel, Aug. 06, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the ...
News, Short Squeeze, Breakout and More Instantly...
YAVNE, Israel, Aug. 02, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the second quarter ended June 30, 2024 on Wednesday, August 14, 20...
Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in ne...
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd....